Arvinas Inc (ARVN) - News Archive

Arvinas Showcases Promising Preclinical Efficacy of ARV-806 in KRAS G12D-Mutated Cancers Amidst Notable Revenue Surge New Haven, Connecticut Arvinas Inc., a clinical-stage biotechnology company known for its pioneering...

In a significant advancement for breast cancer treatment, the latest findings from the VERITAC-2 clinical trial have revealed that vepdegestrant, a promising therapeutic agent, offers notable benefits for patients grapp...

Arvinas Inc. and Pfizer recently shared pioneering initial data from their TACTIVE-U sub-study at the 2024 San Antonio Breast Cancer Symposium. This collaboration is exploring the therapeutic potential of Vepdegestrant...

The landscape of breast cancer therapy is profoundly evolving, particularly with the emergence of innovative treatments targeting estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (H...

Arvinas, a biopharmaceutical company focused on developing targeted protein degradation therapies, recently announced the presentation of preclinical data for two of its PROTAC investigational programs at various scient...

Clinical Data Reinforce Potential of Vepdegestrant in Combination with Palbociclib: Observations and Implications for Arvinas and Pfizer Arvinas and Pfizer have jointly announced promising updates from their Phase 1b cl...

Arvinas, Inc., a well-known American biopharmaceutical company, has announced its plans to present two posters featuring enriched clinical trial data on the investigational drug Vepdegestrant at the 2024 European Societ...

Breaking: Arvinas Strikes Major Deal with Novartis for Prostate Cancer Treatment DevelopmentArvinas, a renowned biopharmaceutical company specializing in targeted protein degradation, has recently announced a groundbrea...

Arvinas Inc., a leading biotechnology company specializing in targeted protein degradation, has recently announced the transition of its Chief Financial Officer (CFO), Sean Cassidy, effective February 29, 2024. This sig...

Arvinas Inc., a leading biopharmaceutical company specializing in targeted protein degradation, has taken significant steps to strengthen its legal capabilities with the appointment of Jared Freedberg as General Counsel...

Arvinas and Pfizer have recently released interim data from a Phase 1b trial of Vepdegestrant, in combination with Palbociclib (IBRANCE), and have announced plans to expand the Vepdegestrant development program. The fin...

Arvinas Announces Oversubscribed $350 Million Private PlacementArvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing drugs based on targeted protein degradation, has disclosed an upc...